Retension Pharmaceuticals, Inc. Common Stock (RTSN)
$11.30▼ −0.53%
Close Nov 2, 2026 · split-adjusted
Oct 30, 2026$11.36▲ 7.88% in range
Oct 9, 2026Low $10.53 · High $16.33Oct 30, 2026
What changed · written from our data
As of Nov 2, 2026
Retension Pharmaceuticals closed at $11.30 on Nov 2, down 0.53%, 30.8% below its highest close since Oct 9. Volume of 71.3K shares was 0.46× its 20-day average (below normal).
Short interest was 62.0K shares at the Oct 15 settlement (0.9% of float, 1.0 days to cover).
No recent articles focused on Retension Pharmaceuticals.
Quick answers
What does Retension Pharmaceuticals do?
Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.
What is RTSN's market cap?
$94.15M, based on the Nov 2 close of $11.30.
How much of RTSN is sold short?
62.0K shares, 0.9% of float, as of Oct 15, 2026.
About Retension Pharmaceuticals
Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology